Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H3 lysine 27 trimethylation (H3K27me3) is a critical repressive epigenetic mark that plays a fundamental role in chromatin organization, gene silencing, and transcriptional regulation. It is catalyzed primarily by the Polycomb Repressive Complex 2 (PRC2), where the methyltransferase Enhancer of Zeste Homolog 2 (EZH2) or its paralog EZH1 serves as the catalytic subunit. Conversely, the modification is removed by the Jumonji-domain-containing demethylases JMJD3 (KDM6B) and UTX (KDM6A). Aberrant hyper-trimethylation of H3K27 is a well-established hallmark of various malignancies, including lymphomas, leukemias, and solid tumors, where it leads to the epigenetic silencing of tumor suppressor and pro-differentiation genes. Pharmacological modulation of H3K27me3 has emerged as a powerful therapeutic strategy in oncology. Small-molecule inhibitors targeting EZH2 (such as tazemetostat) or dual EZH1/2 inhibitors (such as valemetostat and tulmimetostat) effectively reduce global H3K27me3 levels, thereby restoring the expression of silenced genes and promoting tumor cell differentiation or apoptosis. Additionally, embryonic ectoderm development (EED) inhibitors disrupt the PRC2 complex to achieve similar epigenetic reactivation. Conversely, demethylase inhibitors like GSK-J4 can be used to elevate H3K27me3 levels in specific contexts.
Drugs modulate H3K27me3 levels by inhibiting the enzymes responsible for its deposition (writers) or removal (erasers), or by disrupting the protein-protein interactions required for its propagation. Specifically, EZH2/EZH1 inhibitors block the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) to prevent the transfer of methyl groups from S-adenosylmethionine (SAM) to H3K27, thereby reducing H3K27me3 levels and reactivating silenced genes. EED inhibitors bind to the H3K27me3-binding pocket of EED, disrupting PRC2 allosteric activation and leading to a loss of H3K27me3. Conversely, JMJD3/UTX demethylase inhibitors block the removal of methyl groups, thereby increasing H3K27me3 levels.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H3 lysine 27 trimethylation (H3K27me3).